AOA in Recurrent Fertilization Failure (AOA)

Assisted Oocyte Activation (AOA) in Recurrent Fertilization Failure

Background: Despite the high success rate of ICSI, total fertilization failure still occurs in 1-3% of all ICSI cycles and can recur in subsequent cycles, even when a sufficient number of oocytes and motile spermatozoa are available. Several reports show that the majority of couples suffering from ICSI failure benefit from the application of ICSI combined with assisted oocyte activation. A variety of artificial activating methods is used in human assisted reproduction treatment, including physical, mechanical or chemical stimuli, which provoke one or more calcium rises in the oocyte cytoplasm. Study Design: Randomized controlled trial. Setting: A university fertility center. Methods: 150 infertile patients who underwent ICSI and all had history of recurrent fertilization failure. The patients were randomly allocated into 2 equal groups. Group1=75 patients who underwent ICSI without oocyte activation. Group2 patients =75 and underwent ICSI Patient underwent ICSI with oocyte activation. Reproductive outcomes were compared between both groups. Results: there were significant differences between groups regarding number of oocytes retrieved, number of mature oocyte, fertilization rate and pregnancy rate. Conclusion: Assisted oocyte activation with calcium ionophore results in significant improvement in the fertilization, cleavage and pregnancy rates after ICSI.

Study Overview

• Status: Completed
• Conditions: Infertility Primary
• Intervention / Treatment: Drug: Calcium Ionophore A23187

Detailed Description

This study is a randomized controlled trial included 150 ICSI patients with history of recurrent fertilization failure. Patients had undergone ICSI trials in ART unit, Al-Azhar University, Cairo, Egypt, from July 2017 to November 2018. The study was approved by the university medical ethical committee (under registry number 202010454) and all couples had signed a written consent before initiation of the study and the treatment cycles. AOA candidate couples were counseled regarding the procedure. The patients were selected according to the following criteria:

Inclusion Criteria: -

1. Age between 20 and 40 years old.
2. Cases with history of total fertilization failure in previous ICSI cycles
3. Oocytes with normal morphology.
4. Male factor infertility. Exclusion Criteria: - Abnormal oocyte morphology degenerated or immature oocytes.

Two groups were randomly designated:

The first Group: The oocytes were treated by calcium ionophore. This group involved 75 ICSI cycles.

The Second Group: Oocytes were not treated by calcium ionophore. This group involved 75 ICSI cycles.

Methods:

1. Ovarian stimulation:

   All women received ovarian stimulating drugs according to the ART protocols (long agonist, flare up or antagonist protocols). Deca 0.1 was given s.c. daily, for down-regulation in short and long protocol while cetrotide 0.25 was given s.c. daily for down-regulation in antagonist protocol. Follicular development was monitored by ultrasound scanning and serum estradiol. Patients received 10,000 IU of Human Chronic Gonadotrophin (HCG) when most of the follicles measured more than 17-20 mm in diameter.

2. Semen preparation:

   • The husband was asked to submit a semen sample in a sterile plastic container after a 2 to 3-day period of abstinence and about 2 hours before the ICSI procedure. The specimen container must be clean, sterile and wide mouthed to minimize collection error.

3. Oocyte retrieval:

   • Under general anesthesia, the oocytes were aspirated by a specialized, ultrasound-guided needle (Labotect aspiration catheter, Germany) at 34-36 h after HCG injection. Warmed HEPES buffered medium (Irvine Scientific, Irvine, CA, USA) was used for handling and washing of oocytes.
   • After ICSI, the whole injected oocytes were washed with Global total Fertilization Medium (Global pharm, Life Global, Brussels, Belgium, Europe) and the patients were randomly allocated into two equal groups (75 patients each) by using computer-based randomization program. Group one in which, the injected oocytes were transferred to a medium that contain 10 µmol of calcium ionophore (GM508 Cult-Active, Gynemed, Germany) and were incubated for 10 minutes, then again oocytes were washed with Global total Fertilization Medium (Global pharm, Life Global, Brussels, Belgium, Europe) and were incubated at 37°C in 6% CO2. In group two, the injected oocytes were not submitted to calcium ionophore activation.
   • 18 hours after injection, the whole injected oocytes in both groups were evaluated for fertilization, cleavage and quality at the day of embryo transfer (ET).

Embryo Transfer

• After ET, luteal phase support was conducted (intramuscularly progesterone injection 100 mg daily) for 14 days until pregnancy test.

After data collection, both groups were compared regarding oocyte number, oocyte fertilization rate, number and quality of embryos, implantation rate and clinical pregnancy rate.

• Study Type: Interventional
• Enrollment (Actual): 150
• Phase: Phase 4

Contacts and Locations

Study Locations

• Egypt
  • Nasr City
    • Cairo, Nasr City, Egypt, 17151
      • Al-Azhar University

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 16 years to 36 years (Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: Female

Description

Inclusion Criteria:

• (1) Age between 20 and 40 years old. (2) Cases with history of total fertilization failure in previous ICSI cycles (3) Oocytes with normal morphology.

Exclusion Criteria:

• (1) Abnormal oocyte morphology degenerated or immature oocytes. (2) Husbands with spermatogenic arrest or Sertoli/Leydig cells only.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: study group; . This group involved 75 patients with history of fertilization failure in which oocytes were activated by calcium ionophores	Drug: Calcium Ionophore A23187; Calcium Ionophore A23187 is used in laboratories to increase intracellular Ca2+ levels in intact cells. It also uncouples oxidative phosphorylation, the process cells use to synthesize Adenosine triphosphate which they use for energy. In addition, A23187 inhibits mitochondrial ATPase activity. A23187 also induces apoptosis in some cells (e.g. mouse lymphoma cell line, or S49, and Jurkat cells) and prevents it in others (e.g. cells dependent on interleukin 3 that have had the factor withdrawn). In IVF field, Ca Ionophore can be used in case of low fertilization rate after ICSI procedure, particularly with Globozoospermia (Round Head sperm syndrome), Ca Ionophore will replace absence of sperm acrosom, and plays role in oocyte activation after ICSI. Recommended use is 0.5 microgram/ml twice for 10 min interrupted with fresh media with 30 min incubation, followed with regular injected eggs culture for IVF.; Other Names: non
No Intervention: control group; This group involved 75 patients with history of fertilization failure in which oocytes were not activated by calcium ionophores

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
fertilization rate	the number of reproduced embryos divided by the number of fertilized oocytes	one and half year for all patients

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Pregnancy rate	the number of clinically pregnant women divided by the number of total patients undergoing ICSI procedures in the same group	one and half year for all patients

Collaborators and Investigators

• Sponsor: MOHAMED BEHERY
• Investigators: Principal Investigator: doaa DA aswad, Master, specialist of obstetrics and gynecology

Study record dates

Study Major Dates

• Study Start (Actual): July 15, 2017
• Primary Completion (Actual): November 1, 2018
• Study Completion (Actual): November 17, 2018

Study Registration Dates

• First Submitted: February 4, 2021
• First Submitted That Met QC Criteria: February 4, 2021
• First Posted (Actual): February 9, 2021

Study Record Updates

• Last Update Posted (Actual): February 9, 2021
• Last Update Submitted That Met QC Criteria: February 4, 2021
• Last Verified: February 1, 2021

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Infertility; Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Membrane Transport Modulators; Calcium-Regulating Hormones and Agents; Calcium; Ionophores; Calcium Ionophores
• Other Study ID Numbers: 202010454

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: No

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No